Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Dianthus Therapeutics ( (DNTH) ) is now available.
On May 22, 2025, Dianthus Therapeutics, Inc. announced the resignation of Leon O. Moulder, Jr. from its Board of Directors, with Simon Read, Ph.D., appointed as a new Class III director. Dr. Read will also join the Science and Technology Committee and the Nominating and Corporate Governance Committee, receiving compensation in line with the company’s Non-Employee Director Compensation Policy. The company also held its Annual Meeting of Stockholders on the same day, where Marino Garcia and Paula Soteropoulos were elected as Class I directors. Additionally, stockholders approved executive compensation and ratified Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.
Spark’s Take on DNTH Stock
According to Spark, TipRanks’ AI Analyst, DNTH is a Neutral.
Dianthus Therapeutics faces significant challenges in achieving profitability and positive cash flow, despite revenue growth and a solid equity position. Technical indicators provide a neutral outlook, while valuation remains unattractive due to negative earnings.
To see Spark’s full report on DNTH stock, click here.
More about Dianthus Therapeutics
Average Trading Volume: 347,995
Technical Sentiment Signal: Strong Sell
Current Market Cap: $614.6M
See more insights into DNTH stock on TipRanks’ Stock Analysis page.